Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

Протокол NCT03781479
Описание
Статус выполнения
completedResults
Ход выполнения
100%
21.01.2019
23.07.2020
Цели
A two-period, two-treatment, crossover study to evaluate the safety, tolerability and efficacy of amifampridine phosphate in ambulatory patients diagnosed with spinal muscular atrophy (SMA) Type 3.
Организация, проводящая КИ
Catalyst Pharmaceuticals, Inc.
Фаза КИ
II
Количество пациентов
13

Новости и обновления